ArticleFrontiers in cellular and infection microbiology2026
Association between fatty liver and risk of liver failure in patients with acute hepatitis B: a retrospective cohort study.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Fatty liver (FL) is a common comorbidity that has been associated with adverse clinical outcomes in various liver diseases. However, its impact on the prognosis of acute hepatitis B (AHB) remains unclear. This study aimed to evaluate the influence of FL on liver-related outcomes among hospitalized patients with AHB. Methods: A retrospective analysis was conducted on hospitalized patients diagnosed with AHB from January 1, 2010, to December 30, 2023. Demographic and clinical data were collected, and patients were categorized into AHB with FL (AHB-FL) and AHB without FL (AHB-no FL) groups based on imaging and laboratory examinations. Multivariate regression models were utilized to investigate the association between FL and liver-related outcomes, including acute liver failure (ALF), hepatitis B surface antigen (HBsAg) loss, and seroconversion. Kaplan-Meier analysis was performed to assess differences in time to HBsAg loss and seroconversion. Results: A total of 200 eligible patients were included, with 29 (14.5%) in the AHB-FL group and 171 (85.5%) in the AHB-no FL group. The incidence of ALF was significantly higher in the AHB-FL group (34.5% vs. 15.8%, P = 0.02). No significant differences were observed in rates of HBsAg loss (75.9% vs. 82.5%, P = 0.40) or seroconversion (44.4% vs. 53.1%, P = 0.40) between the two groups. Kaplan-Meier analysis indicated comparable times to HBsAg loss (P = 0.07) and seroconversion (P = 0.43). Multivariable analysis confirmed FL as an independent risk factor for ALF (OR 4.61, 95% CI 1.26-16.86; P = 0.02), but not for HBsAg loss (HR 1.60, 95% CI 0.92-2.78; P = 0.10) or seroconversion (HR 1.69, 95% CI 0.80-3.57; P = 0.17). Subgroup analysis indicated a stronger association between FL and ALF in rural patients (P interaction=0.02), suggesting regional differences may affect clinical risks and management. Conclusion: FL constitutes a robust and independent determinant of ALF in AHB patients, sustained after rigorous adjustment for confounding factors. This evidence highlights a specific metabolic aggravation of liver injury, mandating the integration of FL screening into early risk stratification and management protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.